Pancreatic Cancer Drug Daraxonrasib Shows Promise for Lung Cancer Treatment
Daraxonrasib, a newly approved pancreatic cancer drug also known as Rasonque, has demonstrated clinical promise in treating advanced non-small cell lung cancer, shrinking tumors in roughly 30% to 42% of patients with treatment-resistant RAS mutations, according to clinical trial data published in the New England Journal of Medicine.
Targeting RAS Mutations in Advanced Non-Small Cell Lung Cancer
RAS mutations drive roughly 30% of non-small cell lung cancers, according to data from Memorial Sloan Kettering Cancer Center. For decades, researchers considered RAS proteins largely undruggable due to structural challenges that prevented standard therapies from binding to them. Daraxonrasib changes this dynamic by acting as a molecular glue. The drug binds RAS together with a protein called cyclophilin A, forming a complex that blocks destructive signaling pathways and halts uncontrolled tumor growth.
According to Dr. Kathryn Arbour, a thoracic oncologist at Memorial Sloan Kettering Cancer Center and an author of the study, daraxonrasib represents a notable departure from existing options. “We consider the results incredibly promising,” Arbour stated, noting that the therapy targets all major RAS variants found in lung malignancies. Patients dealing with progressive disease after standard chemotherapy and immunotherapy protocols often find few effective alternatives.
Early Trial Outcomes and Survival Metrics
Clinical data from Phase 1 and Phase 2 trials detail measurable responses among heavily pretreated patient cohorts. In an evaluation of 136 advanced non-small cell lung cancer patients, researchers observed a confirmed tumor reduction in about 30% of participants.
In this group, tumors shrank in approximately 42% of patients, with a response duration of 11.5 months. By comparison, standard docetaxel regimens historically yield response rates of 9% to 14% with progression-free survival restricted to 3 to 4.5 months.
Dr. David Hong, deputy chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and lead investigator on the trial, emphasized the clinical reality facing these patients. “Immunotherapy has improved outcomes for many patients with non-small cell lung cancer, but the majority of these cancers eventually progress,” Hong stated.
Managing Safety Profiles and Ongoing Phase 3 Trials
Adverse events remain common during daraxonrasib therapy, requiring careful clinical oversight. At the Phase 3-selected dose, 51% of trial participants experienced a grade 3 or higher adverse event, 71% required dose modifications, and 10% discontinued treatment entirely. Skin rashes affected up to 90% of patients in specific cohorts, alongside gastrointestinal side effects such as nausea, vomiting, diarrhea, and mouth sores. Hong noted that these toxicities are largely manageable when weighed against available alternatives.
The U.S. Food and Drug Administration approved daraxonrasib on August 26, 2026, for previously treated metastatic pancreatic adenocarcinoma, where a 500-patient trial demonstrated a median overall survival of 13.2 months compared to 6.7 months with standard chemotherapy. However, the drug is not yet approved for lung cancer indications. To secure regulatory approval for thoracic malignancies, a larger Phase 3 trial designated RASolve 301 is currently underway. Expected to enroll approximately 420 patients worldwide, the study directly compares daraxonrasib against the chemotherapy drug docetaxel to definitively establish overall and progression-free survival benefits.